Healthcare Industry News:  ultrasound 

Devices Monitoring Neurology Product Launch

 News Release - November 21, 2016

Neural Analytics Announces Commercial Launch of Lucid(TM) M1 Transcranial Doppler Ultrasound System at 9th Annual Society of Vascular and Interventional Neurology Meeting

LOS ANGELES--(Healthcare Sales & Marketing Network)--Neural Analytics Inc., a medical device company developing technology to measure, diagnose and track brain health, today announced the commercial launch of its Lucid™ M1 Transcranial Doppler ultrasound System, a portable brain monitoring system designed to measure cerebral blood flow velocities within the head and neck. The company also said that it has joined the Society of Vascular and Interventional Neurology (SVIN) to support Mission 2020, an initiative to enhance global efforts to improve stroke care worldwide by significantly increasing stroke treatments for eligible patients and reducing global stroke disability. The initiative was unveiled at the SVIN 9th Annual Meeting and 4th Annual Stroke Center Workshop, taking place from November 16-19, 2016 in Brooklyn, New York.

“Over the last several years, the field of interventional neurology has witnessed an innovation explosion that has fundamentally changed the way that we treat stroke to improve patient outcomes. SVIN has set an ambitious goal to treat every eligible stroke patients emergently with mechanical thrombectomy, but this can only be achieved if stroke patients get access to hospitals with mechanical thrombectomy capability within six hours of their symptoms,” said Dr. Dileep Yavagal, MD, Past President of SVIN. “We are gratified that Neural Analytics will support SVIN on this important initiative as their future technologies will assist us in determining if a patient is suffering from a brain blood flow disorder like stroke, potentially leading to faster treatment and better overall outcomes for these patients.”

SVIN will partner with several governmental and industry collaborators to achieve their initiative by focusing on efforts to improve public awareness for stroke symptoms, supporting legislation to encourage rapid triage of stroke patients, establishing financial initiatives to improve access to care for countries without health insurance and encouraging the development of new technologies to improve stroke assessment and treatment. One supporter announced at the meeting was Neural Analytics which demonstrated its Lucid™ System, a device designed to help improve rapid assessment of patients with brain blood flow disorders at the meeting.

“We are pleased to support SVIN on this important initiative to improve stroke treatment worldwide and help reduce the disability associated with this condition,” said Robert Hamilton, Co-Founder & Chief Science Officer of Neural Analytics. “A critical component for effective stroke treatment is determining an accurate diagnosis as quickly as possible in settings inside and outside the hospital. Neural Analytics is developing new and improved portable tools to help expedite the determination and treatment of patients suffering from these brain diseases.”

Globally each year severe blood flow disorders affect more than 30 million people. TBI and stroke contribute the most to the global disease burden for these disorders. There are 2.5 million people affected by TBI each year in the United States, with 14.8 million people affected globally. The cost of TBI care in the U.S. alone totals $77 billion annually and, reliable triage and timely treatment remains unavailable for a vast majority of these patients. Stroke affects about 16 million people and kill an estimated 5.7 million, with an annual U.S. healthcare cost of $104 billion.1,2,3,4

About Neural Analytics Inc.

Neural Analytics was founded in 2013 to create products and services to measure, diagnose and track brain health. They combine leading data science with cutting edge hardware to allow first responders and clinicians to accurately assess and monitor brain health issues. Their devices are designed to be portable, autonomous, reliable, and produce precise and objective physiological measurements for medical responder monitoring of neural disorders.

More information is available at http://www.neuralanalytics.com.

About SVIN Annual Meeting

The SVIN Annual Meeting is a premier academic venue with scientific presentations covering the full spectrum of cerebrovascular diseases and stroke. Participants will have the opportunity to discuss embolectomy, aneurysms and AVMs, subarachnoid and intracranial hemorrhage, endovascular saves and innovative approaches, new device review, international perspectives, and other-related topics.

Sources

1. Ganesalingam, J. Cost Utility Analysis of Mechanical Thrombectomy Using Stent Retrievers in Acute Ischemic Stroke. Stroke. 2015 Sep;46(9):2591-8. doi: 10.1161/STROKEAHA.115.009396. Epub 2015 Aug 6.

2. Saver, J. et. Al. Stent Retriever Thrombectomy after Intraveneous t-PA vs. t_PA alone in stroke. N Engl J Med 2015; 372:2285-2295

3. Ovbiagele, B. et. Al Forecasting the Future of Stroke in the United States. Stroke. 2013. http://stroke.ahajournals.org/content/44/8/2361.abstract,

4. Age Ageing (2009) 38 (1): 4-5.doi: 10.1093/ageing/afn282


Source: Neural Analytics

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps 2 - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps 2 - available on the Apple App Store for iPhone and iPad.